• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

29.08 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Looking Into Mersana Therapeutics's Return On Capital Employed ↗
March 01, 2022
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in... 
Via Benzinga
News headline image
Recap: Mersana Therapeutics Q4 Earnings ↗
February 28, 2022
Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
78 Biggest Movers From Friday ↗
February 14, 2022
Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
February 16, 2022
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
February 11, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
February 10, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI)... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
February 09, 2022
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares... 
Via Benzinga
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
February 09, 2022
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
February 10, 2022
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets ↗
February 03, 2022
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced a  
Via Benzinga
News headline image
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
February 03, 2022
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5... 
Via Benzinga
News headline image
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗
January 06, 2022
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗
January 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
News headline image
Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B ↗
November 30, 2021
Synaffix B.V. has expanded its license agreement with Mersana Therapeutics Inc (NASDAQ: MRSN) for antibody-drug conjugates (ADCs) targeting cancers. The... 
Via Benzinga
News headline image
Mersana Therapeutics's Return On Capital Employed Insights ↗
November 10, 2021
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in... 
Via Benzinga
News headline image
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings ↗
October 08, 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference... 
Via Benzinga
News headline image
45 Stocks Moving In Monday's Mid-Day Session ↗
September 13, 2021
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
September 10, 2021
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
72 Biggest Movers From Yesterday ↗
September 14, 2021
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
News headline image
41 Stocks Moving In Friday's Mid-Day Session ↗
September 10, 2021
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
News headline image
60 Biggest Movers From Friday ↗
September 13, 2021
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
News headline image
Why Are Mersana Therapeutics Shares Trading Lower On Friday? ↗
September 10, 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views ↗
September 10, 2021
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗
September 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap